Although a small molecule activating p53 offers an attractive path for cancer treatment, pharmacological blocking of p53 provides a compelling rationale for developing the inhibitors of p53 in ischemia as well as in neurological disorders and in downregulating mutant p53, which could be helpful in cancers [16,21]. Here, TP53 is linked to cancer.